WARSAW, Poland, April 4, 2013 /PRNewswire/ -- IBM (NYSE: IBM) Blue Gene/Q, the most powerful single architecture supercomputer in Poland, has been chosen by The Interdisciplinary Centre for Mathematical and Computational Modeling, University of Warsaw (ICM) of Poland to support the country's largest biomedical and biotechnological research initiative called, "Centre for Pre-clinical Research and Technology (CePT)." More than 500 life sciences and biomedical researchers, physicians and students, from a consortium led by The Medical University of Warsaw (WUM) and consisting of three universities and seven research centers of the Polish Academy of Sciences, will use the supercomputer and its supporting e-infrastructure to gain further insight into chronic diseases.
"CePT, a EUR 100 million project, aims to support Poland's transition towards more preventive and patient-centric healthcare," said Dr. Robert Sot, Director of CePT, Warsaw University. "The project will allow the medical community to provide a more holistic approach and open collaboration for the development of innovative treatments and drugs that will improve patients' quality of life over the long term."Estimations show that over one-fourth of Poland's aging population has developed at least one or, very often, more chronic diseases such as: cancer, diabetes, heart disease, respiratory conditions, stroke, and neurological disorders. Early detection and timely diagnosis of these diseases translate into well-targeted and optimized healthcare, as well as improved quality of a patient's life. Similar demands could stimulate the need to carry out clinical and pre-clinical tests covering three to five million Polish citizens, and generate massive volumes of valuable health data which can, in turn, be used by laboratories. ICM's new Blue Gene/Q, code named Nostromo, will help scientists process up to 16 terabytes of Big Data per one sequence by running compute-intensive simulations at the speed of 209.7 trillion operations per second. The supercomputer will use algorithms moving beyond the "routine" sequencing of human or animal genomes, to tackle more complex processes that will reveal the rare variants in human genetics, (i.e. those that cause predispositions to Alzheimer's, cancer, diabetes, downs syndrome, etc.). By understanding what prevents protein molecules, which build and maintain human bodies, from folding up properly and triggering a disease, scientists will be able to develop a new drug or treatment, (i.e. "build" their own molecules or block the action of undesirable enzymes).
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts